Potential Therapeutic Roles for Direct Factor Xa Inhibitors in Coronavirus Infections.
Am J Cardiovasc Drugs
; 20(6): 525-533, 2020 Dec.
Article
in English
| MEDLINE | ID: covidwho-755898
ABSTRACT
Human factor Xa (FXa) is a serine protease of the common coagulation pathway. FXa is known to activate prothrombin to thrombin, which eventually leads to the formation of cross-linked blood clots. While this process is important in maintaining hemostasis, excessive thrombin generation results in a host of thrombotic conditions. FXa has also been linked to inflammation via protease-activated receptors. Together, coagulopathy and inflammation have been implicated in the pathogenesis of viral infections, including the current coronavirus pandemic. Direct FXa inhibitors have been shown to possess anti-inflammatory and antiviral effects, in addition to their established anticoagulant activity. This review summarizes the pharmacological activities of direct FXa inhibitors, their pharmacokinetics, potential drug-drug interactions and adverse effects, and the details of clinical trials involving direct FXa inhibitors in coronavirus disease 2019 (COVID-19) patients.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Factor Xa Inhibitors
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Am J Cardiovasc Drugs
Journal subject:
Vascular Diseases
/
Cardiology
/
Drug Therapy
Year:
2020
Document Type:
Article
Affiliation country:
S40256-020-00438-6
Similar
MEDLINE
...
LILACS
LIS